TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04133649
Drug: AAV-hTERT
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
Study: NCT00017459
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017459
Drug: tirapazamine
Normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00017459
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04478461
Drug: PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W
Study: NCT00411398
Drug: Namenda/Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg tablets, 1-4 tabs by mouth per day
Study: NCT01232491
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
Study: NCT00649727
Drug: Oxybutynin Chloride ER Tablets 10 mg
Normalized name: oxybutynin chloride Extended Release Oral Tablet
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x10mg, single dose fed
Study: NCT00135382
Drug: Videx EC
Normalized name: Videx EC
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00135382
Drug: Epivir
Normalized name: Epivir
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00135382
Drug: Sustiva
Normalized name: Sustiva
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02971982
Drug: rituximab /Dexamethasone/cyclophosphamide
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
Study: NCT00671073
Drug: Oglemilast
Normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oglemilast low dose, oral administration, once daily for 12 weeks
Study: NCT00671073
Drug: Oglemilast
Normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oglemilast middle dose, oral administration, once daily for 12 weeks
Study: NCT00671073
Drug: Oglemilast
Normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oglemilast high dose, oral administration, once daily for 12 weeks
Study: NCT01487382
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
Study: NCT01481740
Drug: Phenylephrine bolus
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 ml of 100mcg/ml phenylephrine and placebo infusion
Study: NCT01481740
Drug: phenylephrine infusion
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60ml infusion of 100mcg/ml phenylephrine and placebo bolus
Study: NCT03884101
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
Study: NCT03884101
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
Study: NCT03884101
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
Study: NCT03401073
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
Study: NCT03401073
Drug: 0.9% Sodium Chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
Study: NCT00110344
Drug: Nexavar (Sorafenib, BAY43-9006)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
Study: NCT00553592
Drug: Bicifadine
Normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg/day
Study: NCT00553592
Drug: Bicifadine
Normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT00553592
Drug: Bicifadine
Normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg
Study: NCT00706355
Drug: PF-04217903
Normalized name: PF-04217903
DrugBank: PF-04217903 (DB12848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
Study: NCT00455442
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00937651
Drug: Fimasartan (BR-A-657•K) 20 mg
Normalized name: Respa-BR
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
Study: NCT00937651
Drug: Fimasartan (BR-A-657•K) 60 mg
Normalized name: pyridostigmine
DrugBank: Fimasartan (DB09279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
Study: NCT00937651
Drug: Fimasartan (BR-A-657•K) 180 mg
Normalized name: pyridostigmine
DrugBank: Fimasartan (DB09279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
Study: NCT01838928
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03475628
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
Study: NCT01135628
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide tablets 400 mg, bid, orally for 6 months
Study: NCT01056094
Drug: Lutein
Normalized name: Lutein
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
Study: NCT01229644
Drug: Crenolanib (CP-868,596)
Normalized name: CP
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly potent inhibitor of both PDGFR receptors alpha and beta
Study: NCT03978091
Drug: AZACTAM
Normalized name: Azactam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
Study: NCT03978091
Drug: Ceftazidime-Avibactam
Normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antibacterial combination product containing ceftazidime and avibactam
Study: NCT00705692
Drug: Levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00136578
Drug: SB-715992
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
Study: NCT00136578
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
Study: NCT03695705
Drug: Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
Normalized name: rifAXIMin 550 MG
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
Study: NCT03078582
Drug: Zilucoplan (RA101495)
Normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Study: NCT00750126
Drug: Fludarabine, Busulfan, Thymoglobulin
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: study :~* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~* the effectiveness of the protocol on tumor response~* overall survival
Study: NCT01843348
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01843348
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
Study: NCT01843348
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
Study: NCT01843348
Drug: Mycophenolate mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
Study: NCT01843348
Drug: Simulect
Normalized name: Simulect
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
Study: NCT00003014
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00480623
Drug: Satraplatin plus radiation therapy
Normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04523402
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with GEMOX regimen before liver resection
Study: NCT02546349
Drug: fluticasone/salmeterol, tiotropium
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
Study: NCT03465436
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg administered orally (PO)
Study: NCT03465436
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg administered PO
Study: NCT03465436
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg moxifloxacin administered PO
Study: NCT02972502
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive 10 mg of intravenous (IV) metoclopramide.
Study: NCT02972502
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive 2.5 mg of IV haloperidol.
Study: NCT02972502
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients receive 25 mg of intravenous (IV) diphenhydramine.
Study: NCT00117403
Drug: Coenzyme Q
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg, compounded as a wafer, two wafers three times per day with meals
Study: NCT05542979
Drug: HH-003 injection
Normalized name: HH-009
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HH-003 injection is administrated via I.V. infusion
Study: NCT03603938
Drug: potassium losartan
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treated with bedtime or awakening doses of potassium losartan
Study: NCT01933464
Drug: Cromolyn Sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03290287
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
Study: NCT03290287
Drug: Other COPD medication
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol
Study: NCT04176588
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:Etrasimod Tablet other name:APD334
Study: NCT01312311
Drug: Docetaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
Study: NCT01352728
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
Study: NCT00002714
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002714
Drug: mechlorethamine hydrochloride
Normalized name: Mechlorethamine hydrochloride
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002714
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002714
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002714
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00468078
Drug: F-18 FPCIT
Normalized name: F-18-fpcit
DrugBank: Ioflupane F-18 (DB16913)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mCi, intravenous injection
Study: NCT02035020
Drug: gamma interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
Study: NCT03580291
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This group receive oral MMF of 2.0 g / d.
Study: NCT03763760
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study: NCT00563680
Drug: AMG 479
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
Study: NCT00925301
Drug: migalastat hydrochloride
Normalized name: Migalastat hydrochloride
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral capsule QOD
Study: NCT04465539
Drug: Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]
Normalized name: hydroxyethyl starch 130-0.4 60 MG/ML [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch dose is 500 cc in 6 hours
Study: NCT04167176
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.5% will be included in the injected LA mixture.
Study: NCT04167176
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 2% will be included in the injected LA mixture.
Study: NCT00603291
Drug: Lorcaserin 10 mg once daily (QD)
Normalized name: lisinopril
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
Study: NCT00603291
Drug: Lorcaserin 10 mg twice a day (BID)
Normalized name: lorcaserin hydrochloride 10 MG
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
Study: NCT00770692
Drug: Eszopiclone 1 mg- Elderly
Normalized name: eszopiclone 1 MG
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
Study: NCT00770692
Drug: Eszopiclone 2 mg- Elderly
Normalized name: eszopiclone 2 MG
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.
Study: NCT00770692
Drug: Eszopiclone 3 mg- Non-elderly
Normalized name: eszopiclone 3 MG
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.
Study: NCT00770692
Drug: Eszopiclone 2 mg- Non-elderly
Normalized name: eszopiclone 2 MG
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
Study: NCT00293202
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
Study: NCT01079884
Drug: esomeprazole 40 mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg daily for 4 weeks
Study: NCT00734201
Drug: V24343
Normalized name: V24343
DrugBank: V24343 (DB05201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
Study: NCT02059330
Drug: Palbociclib 75mg
Normalized name: PALBOCICLIB 75MG TAB
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Study: NCT02059330
Drug: Palbociclib 125mg
Normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Study: NCT02059330
Drug: Palbociclib 100mg
Normalized name: PALBOCICLIB 100MG TAB
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.